2024
Association between Immunoparesis and treatment outcomes of patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-analysis
Siwakoti A, Khadka S, Grimshaw A, Giri S. Association between Immunoparesis and treatment outcomes of patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-analysis. Clinical Lymphoma Myeloma & Leukemia 2024 DOI: 10.1016/j.clml.2024.07.008.Peer-Reviewed Original ResearchNewly diagnosed multiple myelomaProgression free survivalImpact of immunoparesisVisual examination of funnel plotsAssociated with worse OSOverall survivalMultiple myelomaFree survivalPrognostic impactPre-published protocolFunnel plotMeta-analysisHazard ratioTreatment outcomes of patientsPublication biasOutcomes of patientsContour-enhanced funnel plotsImmune system perturbationsInfection rateCause of mortalityInfection riskMicro AbstractClinical outcomesImmunoparesisPolyclonal immunoglobulinsLow skeletal muscle mass and treatment outcomes among adults with haematologic malignancies: A systematic review and meta‐analysis
Anabtawi N, Pasala M, Grimshaw A, Kharel P, Bal S, Godby K, Siwakoti A, Buford T, Bhatia S, Costa L, Williams G, Giri S. Low skeletal muscle mass and treatment outcomes among adults with haematologic malignancies: A systematic review and meta‐analysis. Journal Of Cachexia Sarcopenia And Muscle 2024, 15: 1084-1093. PMID: 38558541, PMCID: PMC11154774, DOI: 10.1002/jcsm.13446.Peer-Reviewed Original ResearchConceptsLow skeletal muscle massNon-relapse mortalityProgression free survivalTreatment-related toxicityHaematological malignanciesOverall survivalSkeletal muscle massMuscle massEffects of low skeletal muscle massImpact of low skeletal muscle massIncreased risk of treatment-related toxicityPresence of low skeletal muscle massRisk of treatment-related toxicityHazard ratioAssociated with worse survival outcomesAssociated with worse OSDerSimonian-Laird random-effects modelModerate heterogeneityInferior overall survivalWorse survival outcomesConfidence intervalsRandom-effects modelFree survivalSolid malignanciesPre-published protocol
2022
Shortening the duration of dual antiplatelet therapy after percutaneous coronary intervention for acute coronary syndrome: A systematic review and meta-analysis
Park DY, Wang P, An S, Grimshaw AA, Frampton J, Ohman EM, Rao SV, Nanna MG. Shortening the duration of dual antiplatelet therapy after percutaneous coronary intervention for acute coronary syndrome: A systematic review and meta-analysis. American Heart Journal 2022, 251: 101-114. PMID: 35654162, PMCID: PMC10904033, DOI: 10.1016/j.ahj.2022.05.019.Peer-Reviewed Original ResearchConceptsMonths of DAPTHazard ratioIschemic eventsDuration of DAPTSelect patient characteristicsDual antiplatelet therapyAcute coronary syndromeCoronary artery lesionsPercutaneous coronary interventionConfidence intervalsAssociation of outcomesRandom-effects modelComprehensive literature searchMeta-regression analysisMajor bleedingAntiplatelet therapyCoronary syndromeArtery lesionsCoronary interventionControlled TrialsPatient characteristicsPrespecified outcomesGreater proportionSimilar efficacySystematic review
2021
Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation–A Systematic Review and Meta-Analysis
Bewersdorf JP, Allen C, Mirza AS, Grimshaw AA, Giri S, Podoltsev NA, Gowda L, Cho C, Tallman MS, Zeidan AM, Stahl M. Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation–A Systematic Review and Meta-Analysis. Transplantation And Cellular Therapy 2021, 27: 997.e1-997.e11. PMID: 34551341, PMCID: PMC9533376, DOI: 10.1016/j.jtct.2021.09.005.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaRelapse-free survivalMaintenance therapyMyelodysplastic syndromeFLT3 inhibitorsAllo-HCTHazard ratioMaintenance treatmentClinical trialsMyeloid leukemiaAllogeneic hematopoietic stem cell transplantationControl groupSystematic reviewAllogeneic hematopoietic cell transplantMeasurable residual disease statusHematopoietic stem cell transplantationMeasurable residual disease testingNon-relapse mortalityHematopoietic cell transplantPre-emptive treatmentResidual disease statusStem cell transplantationFavorable safety profileSame patient cohortRandom-effects modelRisk of Intestinal Necrosis With Sodium Polystyrene Sulfonate: A Systematic Review and Meta‐analysis
Holleck JL, Roberts AE, Marhoffer EA, Grimshaw AA, Gunderson CG. Risk of Intestinal Necrosis With Sodium Polystyrene Sulfonate: A Systematic Review and Meta‐analysis. Journal Of Hospital Medicine 2021, 16: 489-494. PMID: 34328838, DOI: 10.12788/jhm.3655.Peer-Reviewed Original ResearchConceptsSevere gastrointestinal side effectsGastrointestinal side effectsIntestinal necrosisHazard ratioSide effectsComposite outcomeOdds ratioSodium polystyrene sulfonateSystematic reviewSevere gastrointestinal adverse eventsGastrointestinal adverse eventsPooled hazard ratioRisk of biasPooled odds ratioCase-control studyPrior systematic reviewsSystematic literature searchAdverse eventsAlternative medicationsCochrane LibraryDatabase inceptionClinical trialsNecrosis rateInclusion criteriaPotential confounding
2020
Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors
Giri S, Grimshaw A, Bal S, Godby K, Kharel P, Djulbegovic B, Dimopoulos MA, Facon T, Usmani SZ, Mateos MV, Costa LJ. Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors. JAMA Oncology 2020, 6: 1759-1765. PMID: 32970151, PMCID: PMC7516804, DOI: 10.1001/jamaoncol.2020.4338.Peer-Reviewed Original ResearchConceptsProgression-free survivalHigh-risk MMBackbone regimensRefractory MMHazard ratioMultiple myelomaClinical trialsSystematic reviewDerSimonian-Laird random-effects modelPhase 3 trialImproved response ratesPreferred Reporting ItemsRandom-effects modelCochrane riskSame regimenCytogenetic riskCochrane LibraryMeeting libraryI2 statisticImproved outcomesMAIN OUTCOMEThird investigatorCochran's QPatientsReporting Items